Agertoft, L., and S. Pedersen. 1994. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respiratory Medicine 88:373–381.
American Academy of Pediatrics, Committee on Drugs. 1977. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics 60:91–101.
American Academy of Pediatrics, Committee on Drugs. 1995. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations (RE9503). Pediatrics 95(2):286–294.
Andersson, K. E., A. Bertler, and G. Wettrell. 1975. Post-mortem distribution and tissue concentrations of digoxin in infants and adults. Acta Paediatrica Scandinavica 64(3):497–504.
Aranda, J. V., J. M. Collinge, R. Zinman, and G. Watters. 1979. Maturation of caffeine elimination in infancy. Archives of Disease in Children 54:946–949.
Bajpai, M., L. K. Roskos, D. D. Shen, and R. H. Levy. 1996. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metabolism and Disposition 24:1401–1403.
Bartholome, W. G. 1977. The ethics of non-therapeutic clinical research on children. In Appendix to Report and Recommendations: Research Involving Children. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. DHEW Publication No. (OS) 77-0005:3–17.
Bartholome, W. G. 1996. Ethical issues in pediatric research. In The Ethics of Research Involving Human Subjects. Edited by Harold Y. Vanderpool. Frederick, Md.: University Publishing Group. 356, 360–361.
Bourgeois, B. F. D., and W. E. Dodson. 1983. Phenytoin elimination in newborns . Neurology 33:173–178.
Brown, R. D., G. L. Kearns, and J. T. Wilson. 1993. Integrated pharmacokinetic (PKN)/pharmacodynamic (PDN) model for acetaminophen and ibuprofen antipyresis in children. Clinical Pharmacology and Therapeutics 53.
Brown, R. D., G. L. Kearns, and J. T. Wilson. 1998. Integrated pharmacokinetic-pharmacodynamic model for acetaminophen, ibuprofen, and placebo antipyresis in children. Journal of Pharmacokinetics and Biopharmacology 25:559.
Burtin, P., E. Jacqz-Aigrain, P. Girard, R. Lenclen, J. F. Magny, P. Betremieux, C. Tehiry, L. Desplanques, and P. Mussat. 1994. Population pharmacokinetics of midazolam in neonates. Clinical Pharmacology and Therapeutics 56:615–625.
Busse, W., S. P. Banks-Schlegel, and G. L. Larsen. 1995. Childhood versus adult-onset asthma. American Journal of Respiratory Critical Care Medicine 151:1635–1639.
Cazenave, C., G. Pons, E. Rey, J. M. Treluyer, T. Cresteil, G. Thiroux, P. D'Athis, and G. Olive. 1994. Biotransformation of caffeine in human liver microsomes from fetuses, neonates, infants and adults. British Journal of Clinical Pharmacology 37: 405–412.
Chiba, K., T. Ishizaki, H. Miura, and K. Minigawa. 1980. Michaelis-Menten pharmacokinetics of diphenylhydantoin and application in the pediatric age patient. Journal of Pediatrics 96:479–484.
Craig, W. A. and D. Andes. 1996. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatric Infectious Disease Journal 15(3):255–259.
Cresteil, T. 1998. Onset of xenobiotic metabolism in children: Toxicological implications. Food Additives and Contaminates 15(Suppl.):45–51.
Cresteil, T. 1999. The development of metabolic mechanisms for xenobiotics. Nestle Nutrition Workshop Series, Vol. 44.
Cresteil, T., P. Beaune, P. Kremers, J. P. Flinois, and J. P. Leroux. 1982. Drug-metabolizing enzymes in human fetal liver: Partial resolution of multiple cytochromes P-450. Pediatric Pharmacology 2:199–207.
Cresteil, T., P. Beaune, P. Kremers, C. Celier, F. P. Guengerich, and J. P. Leroux. 1985. Immunoquantification of epoxide hydrolase and cytochrome P-450 isozymes in fetal and adult human liver microsomes. European Journal of Biochemistry 151:345–350.
Cummin, R. G., P. Mitchell, and S. R. Leeder. 1997. Use of inhaled corticosteroids and the risk of cataracts. New England Journal of Medicine 337:8–14.
de Wildt, S. N., G. L. Kearns, J. S. Leeder, and J. N. van den Anker. 1999a. Glucuronidation in humans: Pharmacogenetic and developmental aspects. Clinical Pharmacokinetics 36:439–452.
de Wildt, S. N., G. L. Kearns, J. S. Leeder, and J. N. van den Anker. 1999b. Cytochrome P450 3A: Ontogeny and drug disposition. Clinical Pharmacokinetics 37(6):485-505.
DHHS (U.S. Department of Health and Human Services). 1983. Federal Policy for the Protection of Human Subjects: Additional Protections for Children Involved as Subjects in Research. Federal Register 48:9818. (codified at 45 CFR §46.404–406).
DHHS. 1991a. Federal Policy for the Protection of Human Subjects: Basic Policy for the Protection of Human Research Subjects . Federal Register 56:28003. (codified at 45 CFR §46A).
DHHS. 1991b. Federal Policy for the Protection of Human Subjects: Additional Protections for Children Involved as Subjects in Research (Technical Amendment). Federal Register 56:28032. (codified at 45 CFR §46.404–406).
DuBuske, L. M., J. Grossman, and L. M. Dube. 1997. Randomized trial in patients with moderate asthma: Effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. American Journal of Managed Care 3:633–640.
Ellenberg, S. S., N. Geller, R. Simon, and S. Yusuf (eds). 1993. Proceedings of "Practical Issues in Data Monitoring of Clinical Trials." Statistics in Medicine 12:415–616.
FDA (U.S. Food and Drug Administration). 1992. New drug antibiotic and biological drug product regulations: Accelerated approval. Proposed Rule 57 Federal Register.
FDA. 1996. Guidance for Industry: E6 Good Clinical Practice: Consolidated Guidance. Bethesda, Md.: Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. April 1996.
FDA. 1997a. Food and Drug Administration Modernization Act of 1997. Section III. The pediatric exclusivity provision.
FDA. 1997b. Good clinical practice: Consolidated guidance (FDA guidance document). Federal Register 62:25691–25709.
FDA. 1998a. Pulmonary and Allergy and Endocrinology Advisory Committees Meeting. Bethesda, Md.: U.S. Food and Drug Administration. July 30–31, 1998.
FDA. 1998b. Draft Guidance: General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products. Bethesda, Md.: U.S. Food and Drug Administration. November 10, 1998.
FDA. 1998c. Guidance for Industry: General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products. Bethesda, Md.: Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. November, 1998.
FDA. 1998d. Statistical principles for clinical trials (FDA guidance document). Federal Register 63: 49583–49598.
FDA. 1998e. Regulations requiting manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients. 63 Federal Register 66632–66672. (codified at 21CFR Parts 201, 312, 314 and 601).
FDA. 1999. Guidance for Industry: Population Pharmacokinetics. Bethesda, Md.: Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. February 1999.
Fleming, T. R. and D. L. DeMets. 1993. Monitoring of clinical trials: Issues and recommendations. Controlled Clinical Trials 14(3): 183–197.
Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Sehentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrobial Agents and Chemotherapy 37:1073–1081.
Freedman, B. 1987. Equipoise and the ethics of clinical research. New England Journal of Medicine 317(3):141–145.
Fritz, S., W. Lindner, I. Roots, B. M. Frey, and A. Küpfer. 1987. Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. Journal of Pharmacology and Experimental Therapies 241:615–622.
Garbe, E., J. LeLorier, J.F. Boivin, and S. Suissa. 1997. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. Journal of the American Medical Association 277:722–727.
Garbe, E., S. Suissa, and J. LeLorier. 1998. Association of inhaled corticosteroid use with cataract extraction in elderly patients. Journal of the American Medical Association 280:539–543.
Gorodischer, R., W. J. Jusko, and S. J. Yaffe. 1976. Tissue and erythrocyte distribution of digoxin in infants. Clinical Pharmacology and Therapeutics 19(3):256–264.
Gotschall, R. R., J. S. Leeder, S. M. Abdel-Rahman, M. McCubbin, M. D. Reed, H. C. Farrar, and G. L. Kearns. 1999a. CYP1A2 activity in cystic fibrosis: Lack of concordance with caffeine plasma clearance. Pediatric Pulmonology (Suppl. 19):210.
Gotschall, R. R., K. Marcucci, J. S. Leeder, and G. L. Kearns. 1999b. Cisapride biotransformation: Not all CYP3As are created equal. Clinical Pharmacology and Therapeutics 65:127.
Green, S. J., T. R. Fleming, and J. R. O'Fallon. 1987. Policies for study monitoring and interim reporting of results. Journal of Clinical Oncology 5(9):1477–1484.
Haahtela, T., M. Jarvinen, T. Kava, K. Kiviranta, S. Koskinen, K. Lehtonen, K. Nikander, T. Persson, O. Selroos, and A. Sovijarvi. 1994. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. New England Journal of Medicine 331:700–705.
Hakkola, J., M. Pasanen, R. Purkunen, S. Saarikoski, O. Pelkonen, J. Maenpaa, A. Rane, and H. Raunio. 1994. Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver. Biochemical Pharmacology 48:59–64.
Hamilton, A., I. Failerman, P. Stober, R. M. Watson, and P. M. O'Byrne. 1998. Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early and late phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. Journal of Allergy and Clinical Immunology 102:177–183.
Holgate, S. T., P. Bradding, and A. P. Sampson. 1996. Leukotriene antagonists and synthesis inhibitors: New directions in asthma therapy. Journal of Allergy and Clinical Immunology 98:1–13.
ICH E-11: Investigation of Medicinal Products in the Pediatric Population. October 1999.
In, K. H., K. Asano, D. Beier, J. Grobholz, P. W. Finn, E. K. Silverman, E. S. Silverman, T. Collins, A. R. Fischer, T. P. Keith, K. Serino, S. W. Kim, G. T. De Sanctis, C. Yandava, A. Pillari, P. Rubin, J. Kemp, E. Israel, W. Busse, D. Ledford, J. J. Murray, A. Segal, D. Tinkleman, and J. M. Drazen. 1997. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. Journal of Clinical Investigation 99(5):1130–1137.
Israel, E., J. Cohn, L. Dube, and J. M. Drazen. 1996. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. Journal of the American Medical Association 275:931–936.
Jacqz-Aigrain, E., C. Funck-Brentano, and T. Cresteil. 1993. CYP2D6 and CYP3A-dependent metabolism of dextromethorphan in humans: Fetal and adult studies. Pharmacogenetics 3:197–204.
Kashuba, A. D. M., A. N. Nafziger, and G. L. Kearns. 1998. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6 and CYP3A as determined by phenotyping. Clinical Pharmacology and Therapeutics 64:257–268.
Kearns, G. L. 1998. Pharmacokinetics in infants and children. Inflammatory Bowel Diseases 4(2): 104–107.
Kearns, G. L., D. J. Murry, C. Oermann, A. Gaedigh, M. Sockrider, D. K. Seilheimer, and J. S. Leeder. 1999. Ibuprofen pharmacokinetics in cystic fibrosis: Association with CYP2C9 genotype. Pediatric Pulmonology (Suppl. 19):208.
Kemp, J.P., R. J. Dockhorn, G. G. Shapiro, H. H. Nguyen, T. F. Reiss, B.C. Seldenberg, and B. Knorr. 1998. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. Journal of Pediatrics 133:4244–28.
Kerr, B. M., K. E. Thummel, C. J. Wurden, S. M. Klein, D. L. Kroetz, F. J. Gonzalez, and R. H. Levy. 1994. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochemistry and Pharmacology 47:1969–1979.
Kinirons, M. T., D. O'Shea, R. B. Kim, J. D. Groopman, K. E. Thummel, A. J. J. Wood, and G. R. Wilkinson. 1999. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clinical Pharmacology and Therapeutics 66:224–231.
Knorr, B., J. Matz, and J. A. Bernstein. 1998. Montelukast for chronic asthma in 6- to 14-year-old children: A randomized, double-blind trial. Pediatric Montelukast Study Group. Journal of the American Medical Association 279:1181–1186.
Kolars, J. C., K. C. Lown, P. Schmiedlin-Ren, M. Ghosh, C. Fang, S. A. Wrighton, R. M. Merion, and P. B. Watkins. 1994. CYP3A gene expression in human gut epithelium. Pharmacogenetics 4:247–259.
Komori, M., K. Nishio, M. Kitada, K. Shiramatsu, K. Muroya, M. Soma, K. Nagashima, and T. Kamataki. 1990. Fetus-specific expression of a form of cytochrome P-450 in human livers. Biochemistry 29:4430–4433.
Koren, G., D. B. Carmeli, Y. S. Carmeli, and R. Haslam. 1993. Maturity of children to consent to medical research: The babysitter test. Journal of Medical Ethics 19(3):142–147.
Korinthenberg, R., C. Haug, and D. Hannak. 1994. The metabolization of carbamazepine to CBZ-10,11-epoxide in children from the newborn age to adolescence. Neuropediatrics 25:214–216.
Kraus, D. M., J. H. Fischer, S. J. Reitz, S. A. Kecskes, T. F. Yeh, K. M. McCulloch, E. C. Tung, and M. J. Cwik. 1993. Alterations in theophylline metabolism during the first year of life. Clinical Pharmacology and Therapeutics 54:351–359.
Kroetz, D. L., B. M. Kerr, and L. V. McFarland. 1993. Measurement of in-vivo microsomal epoxide by drolase activity in white subjects. Clinical Pharmacology and Therapeutics 53:306–315.
Lacroix, D., M. Sonnier, A. Moncion, G. Cheron, and T. Cresteil. 1997. Expression of CYP3A in the human liver: Evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. European Journal of Biochemistry 247: 625–634.
Laitinen, A., A. Altraja, M. Kampe, M. Linden, I. Virtanen, and L. Laitinen. 1997. Tenascin is increased in airway basement membrane of asthmatics and decreased by an inhaled steroid. American Journal of Respiratory Critical Care Medicine 156:951–958.
Lambert, G. H., D. A. Schoeller, and A. N. Kotake. 1986. The effect of age, gender and sexual maturation on the caffeine breath test. Developmental Pharmacology and Therapeutics 9:375–381.
Lange, P., J. Parner, J. Vestbo, P. Schnohr, and G. Jensen. 1998. A 15-year follow-up study of ventilatory function in adults with asthma. New England Journal of Medicine 339:1194–1200.
Le Guennec, J. C., and B. Billon. 1987. Delay in caffeine elimination in breast-fed infants. Pediatrics 79:264–268.
Lee, T. H., R. Brattsand, and D. Leung. 1996. Corticosteroid action and resistance in asthma. American Journal of Respiratory and Critical Care Medicine 154 (Suppl.):S1-S79.
Leeder, J. S., and G. L. Kearns. 1997. Pharmacogenetics in pediatrics: Implications for practice. Pediatric Clinics of North America 44:55–77.
Leff, R. D., L. J. Fischer, and R. J. Roberts. 1986. Phenytoin metabolism in infants following intravenous and oral administration. Developmental Pharmacology and Therapeutics 9:217–223.
Leikin, S. 1993. Minors' assent, consent, or dissent to medical research. IRB: A Review of Human Subjects Research 15(2): 1–7.
Leung, D. Y. M., R. J. Martin, S. J. Szefler, E. R. Sher, S. Ying, A. B. Kay, and Q. Hamid. 1995. Dysregulation of inteleukin-4, interleukin-2, and interferon-g gene expression in steroid-resistant asthma. Journal of Experimental Medicine 181:33–40.
Liu, M. C., L. M. Dube, J. Lancaster, and the Zileuton Study Group. 1996. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: 6-month randomized multicenter trial. Journal of Allergy and Clinical Immunology 98:859–871.
Loughnan, P. M., A. Greenwald, W. W. Purton, J. V. Aranda, G. Watters, and A. H. Neims. 1977. Pharmacokinetic observations of phenytoin disposition in the newborn and young infant. Archives of Disease in Childhood 52:302–309.
Mäenpää, J. V. A., O. Pelkonen, T. Cresteil, and A. Rane. 1993. The role of cytochrome P4503A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in adult and fetal liver. Journal of Steroid Biochemistry and Molecular Biology 44:61–67.
McLeod, H. L., E. Y. Krynetski, and J. A. Wilimas. 1995. Higher activity of polymorphic thiopruine S-methyltransferase in erythrocytes from neonates compared to adults. Pharmacogenetics 5:281–286.
Meinert, C. L. 1998. Clinical trials and treatment effects monitoring (with discussion). Controlled Clinical Trials 19:515–543.
Milsap, R. L, and W. J. Jusko. 1994. Pharmacokinetics in the infant. Environmental Health Perspectives 102 (Suppl. 11):107–110.
Murry, D. J., W. R. Crom, W. E. Reddick, R. Bhargava, and W. E. Evans. 1995. Liver volume as a determinant of drug clearance in children and adolescents. Drug Metabolism and Disposition 23:1110–1116.
Nakamura, H., A. Hasegawa, M. Kimura, S. Yamagata, H. Nakasa, H. Osada, S. Sekiya, S. Ohmori, and M. Kitada. 1999. Comparison of urinary 6ß-hydroxycortisol/cortisol ratio between neonates and their mothers. British Journal of Clinical Pharmacology 47:31–34.
Nakamura, H., M. Hirai, S. Ohmori, Y. Ohsone, T. Obonai, K. Sugita, H. Niimi, and M. Kitada. 1998a. Changes in urinary 6ß-hydroxycortisol/cortisol ratio after birth in human neonates. European Journal of Clinical Pharmacology 53:343–346.
Nakamura, Y., M. Hoshino, J. Joon Sim, K. Ishii, K. Hosaka, and T. Sakamoto. 1998b. Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax 53:835–841.
Nassif, E.G., M. M. Weinberger, D. Shannon, S. F. Guiang, L. Hendeles, D. Jimenez, and E. Ekwo. 1981. Theophylline disposition in infancy. Journal of Pediatrics 98:158–161.
National Commission (National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research). 1977. Report and Recommendations: Research Involving Children. DHEW Publication No. 77-0004. 5–7, 126–127, 137.
National Commission. 1979. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects. Federal Register Doc. 79:12065. April 18, 1979. xx.
National Heart, Lung, and Blood Institute. 1995. Global Strategy for Asthma Management and Prevention. Workshop Report. Publication No. 95–3659. Bethesda, Md.: National Heart Lung and Blood Institute.
National Heart, Lung, and Blood Institute. 1997. National Asthma Education and Prevention Program Expert Panel Report II: Guidelines for the Diagnosis and Management of Asthma. Publication No. 97-4051. Bethesda, Md.: National Heart, Lung, and Blood Institute.
Nelson, H. S., I. L. Bernstein, J. Fink, T. B. Edwards, S. L. Spector, W. W. Storms, and D. P. Tashkin for the Pulmicort Turbuhaler Study Group. 1998. Oral glueocorticosteroid-sparing effect of budesonide administered by Turbuhaler. Chest 113:1264–1271.
Nelson, R.M. 1998. Children as research subjects. Pp. 47–66 in Beyond Consent: Seeking Justice in Research, J. Kahn, A. Mastroianni, and J. Sugarman, eds. New York: Oxford University Press.
Noonan, M., P. Chervinsky, and W. W. Busse. 1995. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. American Journal of Respiratory Critical Care Medicine 152:1467–1473.
Olivierie, D., A. Chetta, M. Del Donno, et al. 1997. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: A placebo-controlled study. American Journal of Respiratory Critical Care Medicine 155:1864–1871.
Overbeek, S. E., H. A.M. Kerstjens, J. M. Bogaard, P. G. H. Mulder, D. S. Postma, and the Dutch CNSLD study group. 1996. Is delayed introduction of inhaled corticosteroids harmful in patients with obstructive airways disease (asthma and COPD)? Chest 110:35–41.
Pariente-Khayat, A., G. Pons, E. Rey, M. Richard, P. d'Athis, L. Moran, J. Badoual, and G. Olive. 1991. Caffeine acetylator phenotyping during maturation in infants. Pediatric Research 29:492–496.
Park-Hah, J. O., B. Klemetsdal, R. Lysaa, K. H. Choi, and J. Aarbakke. 1996. Thiopurine methyltransferase activity in a Korean population sample of children. Clinical Pharmacology and Therapeutics 60:68–74.
Payne, K., F. J. Mattheyse, D. Liedenberg, and T. Dawes. 1989. The pharmaeokineties of midazolam in paediatric patients. European Journal of Clinical Pharmacology 37:267–272.
Peat, J. 1998. Asthma: A longitudinal perspective. Journal of Asthma 35:235–241.
Pedersen, S., and O. R. Hansen. 1995. Budesonide treatment of moderate and severe asthma in children: A dose-response study. Journal of Allergy and Clinical Immunology 95:29–33.
Pelkonen, O., E. H. Kaltiala, T. K. I. Larmi, and N. T. Karki. 1973. Comparison of activities of drug-metabolizing enzymes in human fetal and adult livers. Clinical Pharmacology and Therapeutics 14:840–846.
Pynnönen, S., M. Sillanpäa, H. Frey, and E. Iisalo. 1977. Carbamazepine and its 10,11-epoxide in children and adults with epilepsy. European Journal of Clinical Pharmacology 11:129–133.
Ramsey, P. 1970. The Patient as Person: Explorations in Medical Ethics . New Haven: Yale University Press, pp. 25, 36, 39.
Ramsey, P. 1978. Ethical dimensions of experimental research on children. In Research on Children: Medical Imperatives, Ethical Quandaries. Jan Van Eys, ed. Baltimore: University Park Press. Pp. 61–67.
Reiss, T. F., L. C. Altman, P. Chervinsky, A. Bewtram. W. E. Stricker, G. P. Noonan, S. Kundu, and J. Zha. 1996. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. Journal of Allergy and Clinical Immunology 98:528–534.
Relling, M. V., P. L. Harrison, and W. E. Evans. 1999. Cytochrome P450 in normal vs. adult human liver. Clinical Pharmacology and Therapeutics 65:139.
Riva, R., M. Contin, F. Albani, E. Perucca, G. Procaccianti, and A. Baruzzi. 1985. Free concentration of carbamazepine and carbamazepine-10,11-epoxide in children and adults. Influence of age and phenobarbitone co-medication. Clinical Pharmacokinetics 10:524–531.
Schuetz, E.G., J. D. Schuetz, W. M. Grogan, A. Naray-Fejes-Toth, G. Fejes-Toth, J. Raucy, P. Guzelian, K. Gionela, and C. O. Watlington. 1992. Expression of cytochrome P450 3A in amphibian, rat and human kidney. Archives of Biochemistry and Biophysics 294:206–214.
Schuetz, J. D., D. L. Beach, and P. S. Guzelian. 1994. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 4:11–20.
Selroos, O., A. Pietinalho, A. B. Lofroos, and H. Riska. 1995. Effect of early vs. late intervention with inhaled corticosteroids in asthma. Chest 108:1228–1234.
Shapiro, G., L. Mendelson, M. Kraemer, M. Cruz-Rivera, and K. Walton-Bowen. 1998. Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma Journal of Allergy and Clinical Immunology 102:789–796.
Shimada, T., H. Yamazaki, M. Mimura, Y. Inui, and F. P. Guengerich. 1994. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics 270:414–423.
Silverman, M., and S. Pedersen. 1996. Outcome measures in early childhood asthma and other wheezing disorders. European Respiratory Journal 9(Suppl. 21):1S–49S.
Silverman, M., and L. Taussig. 1995. Early childhood asthma: What are the questions? American Journal of Respiratory Critical Care Medicine 151:S1–S42.
Sonnier, M., and T. Cresteil. 1998. Delayed ontogeny of CYP1A2 in the human liver. European Journal of Biochemistry 251:893–898.
Spector, S. L. 1995. Leukotriene inhibitors and antagonists in asthma. Annals of Allergy, Asthma, and Immunology 75:463–470, 473–474.
Spector, S. L., L. J. Smith, and M. Glass. 1994, Effects of 6 weeks of therapy with oral doses of ICI 204, 219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. American Journal of Respiratory Critical Care Medicine 150:618–625.
Tamaoki, J., M. Kondo, N. Sakai, et al. 1997. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. American Journal of Respiratory Critical Care Medicine 155:1235–1240.
Tateishi, T., M. Asoh, A. Yamaguchi, T. Yoda, Y. J. Okana, Y. Koitabashi, and S. Kobayashi. 1999. Developmental changes in urinary elimination of theophylline and its metabolites in pediatric patients. Pediatric Research 45:66–70.
Thomas, J. K., A. Forrest, S. M. Bhavnani, J. M. Hyatt, A. Cheng, C. H. Ballow, and J. J. Schentag. 1998. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy . Antimicrobial Agents and Chemotherapy 42:521–527.
Thummel, K. E., D. O'Shea, M. F. Paine, and D. D. Sherig, K.L. Kunze, J.D. Perkins, and G. Wilkomen. 1996. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clinical Pharmacology and Therapeutics 59:491–502.
Tjia, J. F., J. Colbert, and D. J. Back. 1996. Theophylline metabolism in human liver microsomes: inhibition studies. Journal of Pharmacology and Experimental Therapeutics 276:912–917.
Tran, J. Q., C. H. Ballow, A. Forrest, J. M. Hyatt, M. F. Sands, C. A. Peloquin, and J. J. Schentag. 2000. Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: Influence of pharmacokinetic and pharmacodynamic variables. Journal of Antimicrobial Chemotherapy 45:9–17.
Transon, C., S. Lecoeur, T. Leemann, P. Beaune, and P. Dayer. 1996. Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes. European Journal of Clinical Pharmacology 51:79–85.
Treluyer, J. M., G. Cheron, M. Sonnier, and T. Cresteil. 1996. Sudden infant death syndrome and hepatic cytochrome P450 content. Biochemistry and Pharmacology 52:497–504.
Treluyer, J. M., G. Gueret, G. Cheron, M. Sonnier, and T. Cresteil. 1997. Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in vivo/in vitro correlation and inducibility. Pharmacogenetics 7:441–452.
Treluyer, J. M., E. Jacqz-Aigrain, F. Alvafez, and T. Cresteil. 1991. Expression of CYP2D6 in the developing human liver. European Journal of Biochemistry 202: 583–588.
Vieira, I., M. Pasanen, H. Raunio, and T. Cresteil. 1998. Expression of CYP2E1 in human lung and kidney during development and in full term placenta: A differential methylation of the gene is involved in the regulation process. Pharmacology and Toxicology 83:183–187.
Vieira, I., M. Sonnier, and T. Cresteil. 1996. Developmental expression of CYP2E1 in the human liver: Hypermethylation control of gene expression during the neonatal period. European Journal of Biochemistry 238:476–483.
Wandstrat, T. L., T. J. Schroeder, and S. A. Myre. 1989. Cyclosporine pharmacokinetics in pediatric transplant recipients. Therapeutic Drug Monitor 11:493–496.
Watchko, J. F., M. J. Daood, and T. W. Hansen. 1998. Brain billrubin content is increased in P-glycoprotein-deficient transgenic null mutant mice. Pediatric Research 44(5):763–766.
Watkins, P. B. 1994. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4:171–184.
Weiss, S. T. 1995. Early life predictors of adult chronic obstructive lung disease. European Respiratory Review 5(31):303–309.
Welthorn, L. A. and S. B. Campbell. 1982. The competency of children and adolescents to make informed treatment decisions. Child Development 53(6): 1589–1598.
Wenzel, S. E., S. J. Szefler, D. Y. M. Leung, S. I. Sloan, M.D. Rex, and R. J. Martin. 1997. Bronchoscopic evaluation of severe asthma: Persistent inflammation despite high dose glucocorticoids . American Journal of Respiratory Critical Care Medicine 156:737–743.
Williams, P. C. 1996. Ethical principles in federal regulations: The case of children and research risks. Journal of Medicine and Philosophy 21 (2): 177–183.
Wilson, J. T., R. D. Brown, J. A. Bocchini, and G. L. Kearns. 1982. Efficacy, disposition and pharmacodynamics of aspirin, acetaminophen and choline salicylate in your febrile children. Therapeutic Drug Monitor 4:147.
Wilson, J. T., B. Hojer, and A. Rane. 1976. Loading and conventional dose therapy with phenytoin in children: Kinetic profile of parent drug and main metabolite in plasma. Clinical Pharmacology and Therapeutics 20:48–58.
Wilson, J. T., B. Hojer, G. Thompson, A. Rane, and F. Sjoqvist. 1978. High incidence of a concentration dependent skin reaction in children treated with phenytoin. British Medical Journal 1 (6127): 1583.
Woolcock, A. J., and P. J. Barnes. 1996. Asthma: The important questions. Part 3. American Journal of Respiratory Critical Care Medicine 153(Suppl.):S1–S32.
Yaffe, S. J., A. Rane, F. Sjoqvist, L. O. Boreus, and S. Orrenius. 1970. The presence of a monooxygenase system in human fetal liver microsomes. Life Science 9:1189–1200.